Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareRxFRA:29C1 66 EV-to-FCF is 13.18 as of Aug. 09, 2026, which is 31% above its 10-year median of 10.08. GuruFocus rates FRA:29C1 with a GF Score™ of 66/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review. Among 405 Healthcare Providers & Services companies, CareRx ranks better than 61.98% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CareRx's Enterprise Value is €173.7 Mil.
CareRx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €13.2 Mil. Therefore, CareRx's EV-to-FCF for today is 13.18.
The historical rank and industry rank for CareRx's EV-to-FCF or its related term are showing as below:
FRA:29C1'
s EV-to-FCF Range Over the Past 10 Years
Min: -494.17 Med: 10.08 Max: 2295.18
Current: 13.2
During the past 13 years, the highest EV-to-FCF of CareRx was 2295.18. The lowest was -494.17. And the median was 10.08.
FRA:29C1's EV-to-FCF is ranked better than 61.98% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 18.84
vs FRA:29C1: 13.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-09), CareRx's stock price is €2.04.
CareRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.260. Therefore, CareRx's PE Ratio (TTM) for today is 7.85.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CareRx's share price for today is €2.04.
CareRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CareRx EV-to-FCF Related Terms
CareRx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CareRx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, CareRx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareRx EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CareRx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CareRx's EV-to-FCF falls into.
CareRx's current Enterprise Value is €173.7 Mil.
CareRx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareRx (FRA:29C1) has a EV-to-FCF of 13.18 as of Aug. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CareRx and its competitors. This is 31% above median its historical median of 10.08. According to the industry distribution chart, CareRx ranks #154 out of 405 companies in the Healthcare Providers & Services industry, placing it in the top 38%.
Is CareRx's EV-to-FCF too high?
CareRx's current EV-to-FCF of 13.18 is 31% above median its 10-year median of 10.08. The Healthcare Providers & Services industry median EV-to-FCF is 18.84. CareRx's value of 13.18 is 30% below this industry median. Based on the distribution chart, CareRx ranks #154 out of 405 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, CareRx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's EV-to-FCF compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #154 out of 405 companies for EV-to-FCF. This puts CareRx in the upper half of its industry. The industry median EV-to-FCF is 18.84. CareRx's value of 13.18 is 30% below this benchmark. While the company's 10-year median is 10.08 vs. the industry median of 18.84, CareRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.84, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareRx's current EV-to-FCF of 13.18 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CareRx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareRx's current EV-to-FCF is 13.18, which is 31% above median its own 10-year median of 10.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current EV-to-FCF of 13.18. The stock's GF Value™ is €1.37, compared to a current price of €2.04 — trading 48.9% above its estimated fair value. The current EV-to-FCF is 13.18, which is 31% above median its 10-year median of 10.08 and 30% below the Healthcare Providers & Services industry median of 18.84. CareRx's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CareRx (FRA:29C1), the current EV-to-FCF is 13.18 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareRx (FRA:29C1) Overvalued in 2026?
Based on GuruFocus' analysis, CareRx stock appears to be overvalued.
The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.
Key valuation signals for FRA:29C1:
EV-to-FCF: 13.18 (31% above median its 10-year median of 10.08)
GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
Industry Position: 30% below the Healthcare Providers & Services median (#154 of 405)
No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score
Get the complete analysis for FRA:29C1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:29C1 has been successfully added to your 
